CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 65,600 shares, a growth of 45.1% from the November 30th total of 45,200 shares. Based on an average daily trading volume, of 57,700 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.9% of the company’s shares are sold short.

Insider Buying and Selling at CalciMedica

In other news, insider Eric W. Roberts bought 53,333 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average price of $3.75 per share, with a total value of $199,998.75. Following the purchase, the insider now owns 164,706 shares in the company, valued at approximately $617,647.50. The trade was a 47.89 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the business’s stock in a transaction on Friday, November 1st. The shares were acquired at an average price of $3.75 per share, for a total transaction of $325,751.25. Following the completion of the purchase, the insider now directly owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This trade represents a 11.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 252,744 shares of company stock valued at $942,510 over the last 90 days. 41.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. PVG Asset Management Corp acquired a new stake in CalciMedica in the third quarter valued at $67,000. Geode Capital Management LLC raised its position in shares of CalciMedica by 51.2% during the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares in the last quarter. Finally, Atria Investments Inc boosted its holdings in CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after purchasing an additional 15,296 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a research note on Thursday, November 14th.

CalciMedica Price Performance

Shares of CalciMedica stock traded down $0.17 on Monday, reaching $2.68. 10,466 shares of the company were exchanged, compared to its average volume of 39,103. The stock’s 50 day moving average price is $3.33 and its 200-day moving average price is $4.02. CalciMedica has a 1-year low of $2.05 and a 1-year high of $8.38. The company has a market cap of $36.13 million, a P/E ratio of -2.48 and a beta of 1.25.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.